Related Experiment Video
Updated: Nov 6, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
RNA modifications in cardiovascular diseases, the potential therapeutic targets
Yirong Wu1, Siyao Zhan1, Yizhou Xu1
1Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, 310006 Zhejiang, China.
Abstract:
More than one hundred RNA modifications decorate the chemical and topological properties of these ribose nucleotides, thereby executing their biological functions through post-transcriptional regulation. In cardiovascular diseases, a wide range of RNA modifications including m6A (N6-adenosine methylation), m5C (5-methylcytidin), Nm (2'-O-ribose-methylation), Ψ (pseudouridine), m7G (N7-methylguanosine), and m1A (N1-adenosine methylation) have been found in tRNA, rRNA, mRNA and other noncoding RNA, which can function as a novel mechanism in metabolic syndrome, heart failure, coronary heart disease, and hypertension. In this review, we will summarize the current understanding of the regulatory roles and significance of several types of RNA modifications in CVDs (cardiovascular diseases) and the interplay between RNA modifications and noncoding RNA, epigenetics. Finally, we will focus on the potential therapeutic strategies by using RNA modifications.
Related Concept Videos
Coronary Artery Disease I: Introduction
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Cardiovascular Drugs: Classification based on Therapeutic Indications
Regulation of the Cardiovascular System
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
Atherosclerosis III: Management

